Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could offer a promising development for obesity loss . Initial patient trials https://emilieycjk105210.wikigop.com/333737/a_retatrutide_compound_a_breakthrough_in_body_management